Healios KK (TSE:4593) Other Stockholders Equity: 円-1,706.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4593 Healios KK TSE:4593
50 GF Score
Price 円256.00
GF Value 円56.59
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Healios KK Other Stockholders Equity?

Healios KK TSE:4593 -4.12% 50 Other Stockholders Equity is 円-1,706.00 Mil as of Mar. 2026. GuruFocus rates TSE:4593 with a GF Score™ of 50/100 and a GF Value™ of 円56.59 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Healios KK's Other Stockholders Equity for the quarter that ended in Mar. 2026 was 円-1,706.00 Mil.

Healios KK's quarterly Other Stockholders Equity increased from Sep. 2025 (円-1,747.00 Mil) to Dec. 2025 (円-1,721.00 Mil) and increased from Dec. 2025 (円-1,721.00 Mil) to Mar. 2026 (円-1,706.00 Mil).

Healios KK's annual Other Stockholders Equity increased from Dec. 2023 (円-1,773.00 Mil) to Dec. 2024 (円-1,727.00 Mil) and increased from Dec. 2024 (円-1,727.00 Mil) to Dec. 2025 (円-1,721.00 Mil).

Healios KK Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Healios KK's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Healios KK Other Stockholders Equity Chart

Healios KK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,416.00 -2,979.00 -1,773.00 -1,727.00 -1,721.00

Healios KK Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,750.00 -1,763.00 -1,747.00 -1,721.00 -1,706.00
TSE:4593
50GF Score
Healios KK TSE:4593
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Healios KK Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of 円-1,706.00 Mil mean?
Healios KK (TSE:4593) has a Other Stockholders Equity of 円-1,706.00 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Healios KK and its competitors.
Is Healios KK's Other Stockholders Equity too high?
Healios KK's current Other Stockholders Equity is 円-1,706.00 Mil. Overall, Healios KK has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Healios KK's Other Stockholders Equity compare to VRTX and REGN?
Healios KK's Other Stockholders Equity of 円-1,706.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Healios KK and its competitors. Healios KK's current Other Stockholders Equity is 円-1,706.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healios KK stock overvalued right now?
Based on GuruFocus' analysis, Healios KK (TSE:4593) is currently considered Significantly Overvalued. The stock's GF Value™ is 円56.59, compared to a current price of 円256.00 — trading 352.4% above its estimated fair value. The current Other Stockholders Equity is 円-1,706.00 Mil. Healios KK's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Healios KK (TSE:4593), the current Other Stockholders Equity is 円-1,706.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Healios KK (TSE:4593) Overvalued in 2026?

Based on GuruFocus' analysis, Healios KK stock appears to be overvalued. The current stock price of 円256.00 is trading 352.4% above its estimated GF Value™ of 円56.59. GuruFocus considers Healios KK to be Significantly Overvalued.

Key valuation signals for TSE:4593:

  • Other Stockholders Equity: 円-1,706.00 Mil
  • GF Value™: 円56.59 vs. price of 円256.00 (352.4% above fair value)
  • GF Score™: 50/100 with 5 warning signs

No single metric tells the full story. See the TSE:4593 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Healios KK Business Description

Other Exchanges HLOSF:USA6VX:Germany
Address 1-1-2 Yurakucho, Hibiya Mitsui Tower 12Floor, Work Styling, Chiyoda-ku, Tokyo, JPN, 100-0006
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, ischemic stroke, and acute respiratory distress syndrome.
50GF Score

Get the complete analysis for TSE:4593

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円256.00
Price
円56.59
GF Value